More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.04B
EPS
-1.36
P/E ratio
--
Price to sales
5.35
Dividend yield
--
Beta
0.517385
Previous close
$60.97
Today's open
$60.63
Day's range
$58.88 - $60.97
52 week range
$58.80 - $90.87
show more
CEO
Matthew B. Klein
Employees
991
Headquarters
Warren, NJ
Exchange
Nasdaq Global Select
Shares outstanding
83544284
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
PTC Therapeutics Sees $2 Billion-Plus Sephience Potential, Sets January Guidance Date
PTC Therapeutics NASDAQ: PTCT expects to provide 2027 sales guidance for its oral phenylketonuria treatment Sephience in January, as executives seek to convince investors that the drug's strong first year of sales can be sustained.
MarketBeat • Nov 17, 2026

PTC Therapeutics Board of Directors Authorizes $500 Million Share Repurchase Program
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.
PRNewsWire • Nov 3, 2026

PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows
PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.
Seeking Alpha • Nov 3, 2026

PTC Therapeutics to Participate in Upcoming Investor Conferences
WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 a.m.
PRNewsWire • Nov 2, 2026

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees.
PRNewsWire • Oct 30, 2026

PTC Therapeutics Q3 Earnings Call Highlights
PTC Therapeutics NASDAQ: PTCT reported third-quarter 2026 total revenue of $358 million, including $276 million in net product revenue, as sales of phenylketonuria treatment Sephience continued to expand in the United States and internationally.
MarketBeat • Oct 30, 2026

PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
PTC Therapeutics, Inc. (PTCT) Q3 2026 Earnings Call Transcript
Seeking Alpha • Oct 30, 2026

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – – Full-year 2026 expected total revenue increased to $1.29 to $1.32 billion, with full-year product revenue guidance raised to $960 to $990 million – – Sephience™ (sepiapterin) Q3 2026 revenue of $182 million, with continued growth in the US and ongoing global expansion – – Acquired ST-920 Fabry disease gene therapy; BLA submission expected to be completed in Q4 2026 – WARREN, N.J., Oct. 29, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced a corporate update and financial results for the third quarter ended September 30, 2026.
PRNewsWire • Oct 29, 2026

PTC Therapeutics (PTCT) Q3 Earnings and Revenues Surpass Estimates
PTC Therapeutics (PTCT) came out with quarterly earnings of $0.61 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to earnings of $0.2 per share a year ago.
Zacks Investment Research • Oct 29, 2026

PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for PTC Therapeutics (PTCT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell PTC Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.